Jiangxi Sanxin Medtec Co Ltd

Jiangxi Sanxin Medtec maintains a conservative capital structure with a debt-to-equity ratio of 0.18, indicating limited leverage. The company's liquidity position is characterized as medium risk, with a current ratio of 1.43, suggesting moderate short-term solvency. However, the company reported negative free cash flow of -5.49 million CNY, which may signal pressure on cash generation. Profitability metrics show a return on equity of 17.17% and a return on assets of 10.23%, both exceeding the industry median for medical equipment firms. The gross margin of 35.22% (calculated as 528.39 million CNY gross profit / 1.50 billion CNY revenue) is also above the sector average, indicating strong cost control and pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond China. This concentration increases exposure to domestic regulatory and economic shifts. Analyst estimates suggest a 15.0% year-over-year revenue growth to 1.898 billion CNY, with actual revenue at 1.64 billion CNY in the latest period. Earnings per share (EPS) are expected to rise from 0.51 CNY to 0.61 CNY, reflecting improved profitability. The company faces moderate liquidity risk due to negative free cash flow and a net cash position that is negative after subtracting total debt. Dilution risk is assessed as low, with no recent share issuance or ATM programs disclosed. Capital expenditures of -217.54 million CNY suggest significant reinvestment in operations. Recent filings and transcripts highlight the company's focus on expanding its product portfolio in high-growth medical device categories, including disposable consumables and diagnostic tools. No material regulatory or litigation risks were disclosed in the latest 10-K equivalent filing.